A share price of Axsome Therapeutics Inc [AXSM] is currently trading at $104.46, down -0.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AXSM shares have gain 9.21% over the last week, with a monthly amount drifted -17.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on April 07, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $200. Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $176. On December 31, 2024, Mizuho reiterated its Outperform rating and revised its price target to $122 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $140 on September 03, 2024. BofA Securities upgraded its rating to a Buy and raised its price target to $106 on August 06, 2024. Needham started tracking with a Buy rating for this stock on July 22, 2024, and assigned it a price target of $130. In a note dated April 29, 2024, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $90 to $115.
Axsome Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $64.11 and $139.13. Currently, Wall Street analysts expect the stock to reach $175.25 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $104.46 at the most recent close of the market. An investor can expect a potential return of 67.77% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Trailing Twelve Months sales for Axsome Therapeutics Inc [NASDAQ:AXSM] were 385.69M which represents 66.03% growth. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.73%, Pretax Profit Margin comes in at -0.74%, and Net Profit Margin reading is -0.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -2.9 and Total Capital is -0.83. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 103.74 points at the first support level, and at 103.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 105.42, and for the 2nd resistance point, it is at 106.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Axsome Therapeutics Inc [NASDAQ:AXSM] is 2.11. As well, the Quick Ratio is 2.04, while the Cash Ratio is 1.37. Considering the valuation of this stock, the price to sales ratio is 13.21, the price to book ratio is 89.17.
Transactions by insiders
Recent insider trading involved Pizzie Nick, Chief Financial Officer, that happened on Feb 13 ’25 when 12000.0 shares were sold. Chief Financial Officer, Pizzie Nick completed a deal on Feb 14 ’25 to sell 3000.0 shares. Meanwhile, Officer Pizzie Nick bought 3000.0 shares on Feb 14 ’25.
